Areeba Aamir Ali Basaria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Areeba Aamir Ali Basaria has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Rabeea Tariq
Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan
8 shared publications - Abdullah Nadeem
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
5 shared publications - Aymar Akilimali
Faculty of Medicine University of Goma Goma DR Congo
5 shared publications - Hermann Yokolo
Faculty of Medicine Université Libre des Pays des Grands Lacs Goma DR Congo
5 shared publications - Areeba Ahsan
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Christian Tague
Université Libre Des Pays Des Grands Lacs Goma DR Congo
3 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (10)
Temporal trends and socio-demographic disparities in COPD–lung cancer co-occurrence mortality in the United States: a 22 year analysis (1999–2020)
Background Chronic Obstructive Pulmonary Disease (COPD) and lung cancer remain among the leading causes of mortality worldwide, with a high burden reported in the United States. While both conditions often coexist and share risk factors such as smoking and environmental exposure, temporal mortality trends and disparities across demographics remain underexplored. Objective To analyze age-adjusted mortality rates (AAMRs) associated with the co-occurrence of COPD and lung cancer (COPD–LC) in the United States from 1999 to 2020, with a specific focus on temporal shifts and disparities across sex, race/ethnicity, and geographic regions. Methods Mortality data were retrieved from the CDC WONDER database. The underlying causes of death were identified using ICD-10 codes (J40–J44 for COPD and C33–C34 for lung cancer). AAMRs were standardized to the 2000 U.S. population. Joinpoint regression analysis was used to calculate Annual Percent Changes (APCs) and identify statistically significant shifts in mortality trends. Subgroup analyses were conducted by sex, race/ethnicity, and census regions. Mortality associated with the co-occurrence of COPD and lung cancer was identified using multiple-cause-of-death coding. Results A total of 587,762 deaths involving co-occurring chronic obstructive pulmonary disease (COPD) and lung cancer were identified in the United States between 1999 and 2020. Overall age-adjusted mortality rates (AAMRs) declined from 8.904 per 100,000 population in 1999 to 7.128 in 2020. Joinpoint regression demonstrated a three-segment trend, including a non-significant decline from 1999 to 2006 (APC: − 0.40), a significant decline from 2006 to 2018 (APC: − 1.77%), and a non-significant increase from 2018 to 2020 (APC: 0.71%). Sex-stratified analysis showed persistently higher mortality among males, although mortality declined more substantially in males than in females over time. Non-Hispanic White individuals demonstrated the highest mortality burden, whereas Asian or Pacific Islander and Hispanic populations had the lowest AAMRs. Regionally, mortality rates remained highest in the Midwest and South, while the West exhibited the steepest decline. Non-metropolitan areas demonstrated persistently elevated mortality rates compared with metropolitan regions. Conclusion While mortality among individuals with co-occurring COPD and lung cancer has declined significantly over two decades, demographic disparities based on sex, race, and geography persist. These findings highlight the need for equity-driven public health interventions and early detection strategies tailored to high-risk populations. Graphical abstract
- 30 July 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (10)
Open AccessTemporal trends and socio-demographic disparities in COPD–lung cancer co-occurrence mortality in the United States: a 22 year analysis (1999–2020)
Background Chronic Obstructive Pulmonary Disease (COPD) and lung cancer remain among the leading causes of mortality worldwide, with a high burden reported in the United States. While both conditions often coexist and share risk factors such as smoking and environmental exposure, temporal mortality trends and disparities across demographics remain underexplored. Objective To analyze age-adjusted mortality rates (AAMRs) associated with the co-occurrence of COPD and lung cancer (COPD–LC) in the United States from 1999 to 2020, with a specific focus on temporal shifts and disparities across sex, race/ethnicity, and geographic regions. Methods Mortality data were retrieved from the CDC WONDER database. The underlying causes of death were identified using ICD-10 codes (J40–J44 for COPD and C33–C34 for lung cancer). AAMRs were standardized to the 2000 U.S. population. Joinpoint regression analysis was used to calculate Annual Percent Changes (APCs) and identify statistically significant shifts in mortality trends. Subgroup analyses were conducted by sex, race/ethnicity, and census regions. Mortality associated with the co-occurrence of COPD and lung cancer was identified using multiple-cause-of-death coding. Results A total of 587,762 deaths involving co-occurring chronic obstructive pulmonary disease (COPD) and lung cancer were identified in the United States between 1999 and 2020. Overall age-adjusted mortality rates (AAMRs) declined from 8.904 per 100,000 population in 1999 to 7.128 in 2020. Joinpoint regression demonstrated a three-segment trend, including a non-significant decline from 1999 to 2006 (APC: − 0.40), a significant decline from 2006 to 2018 (APC: − 1.77%), and a non-significant increase from 2018 to 2020 (APC: 0.71%). Sex-stratified analysis showed persistently higher mortality among males, although mortality declined more substantially in males than in females over time. Non-Hispanic White individuals demonstrated the highest mortality burden, whereas Asian or Pacific Islander and Hispanic populations had the lowest AAMRs. Regionally, mortality rates remained highest in the Midwest and South, while the West exhibited the steepest decline. Non-metropolitan areas demonstrated persistently elevated mortality rates compared with metropolitan regions. Conclusion While mortality among individuals with co-occurring COPD and lung cancer has declined significantly over two decades, demographic disparities based on sex, race, and geography persist. These findings highlight the need for equity-driven public health interventions and early detection strategies tailored to high-risk populations. Graphical abstract
- Open Access
- 25 December 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (4) , 6
Unveiling a Giant Hydatid Cyst of the Brain: A Neurosurgical Experience with a Rare Zoonotic Infection
Cerebral hydatid disease is a rare but important manifestation of Echinococcus granulosus, comprising 0.5%–2% of all hydatid cases. It primarily affects children in endemic regions and often remains asymptomatic until the cyst reaches a considerable size, making early diagnosis challenging. An 11-year-old boy from rural Punjab, Pakistan, presented with progressive headache and head enlargement for four months, without seizures or neurological deficits. MRI revealed a large, well-defined cyst (10.9 × 10.2 × 11.2 cm) in the left parieto-occipital region, producing significant mass effect and moderate hydrocephalus. Serology was negative, and systemic imaging ruled out extracranial involvement. The patient underwent parieto-occipital craniotomy, and the cyst was excised intact using the Dowling-Orlando technique to prevent rupture. Histopathology confirmed hydatid disease. Postoperatively, albendazole (10 mg/kg) was administered for 30 days along with anticonvulsants. Recovery was uneventful, and follow-up imaging showed no recurrence. This case underscores the importance of early recognition, meticulous surgical planning, and postoperative monitoring for successful outcomes in cerebral hydatid disease, particularly in endemic areas.
- 25 December 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (4) , 6
Open AccessUnveiling a Giant Hydatid Cyst of the Brain: A Neurosurgical Experience with a Rare Zoonotic Infection
Cerebral hydatid disease is a rare but important manifestation of Echinococcus granulosus, comprising 0.5%–2% of all hydatid cases. It primarily affects children in endemic regions and often remains asymptomatic until the cyst reaches a considerable size, making early diagnosis challenging. An 11-year-old boy from rural Punjab, Pakistan, presented with progressive headache and head enlargement for four months, without seizures or neurological deficits. MRI revealed a large, well-defined cyst (10.9 × 10.2 × 11.2 cm) in the left parieto-occipital region, producing significant mass effect and moderate hydrocephalus. Serology was negative, and systemic imaging ruled out extracranial involvement. The patient underwent parieto-occipital craniotomy, and the cyst was excised intact using the Dowling-Orlando technique to prevent rupture. Histopathology confirmed hydatid disease. Postoperatively, albendazole (10 mg/kg) was administered for 30 days along with anticonvulsants. Recovery was uneventful, and follow-up imaging showed no recurrence. This case underscores the importance of early recognition, meticulous surgical planning, and postoperative monitoring for successful outcomes in cerebral hydatid disease, particularly in endemic areas.
- Open Access
- 26 November 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (12) , e71549
FDA Approves First Targeted Treatment for Cerebrotendinous Xanthomatosis: A Perspective on a Landmark in Rare Lipid Storage Disease Therapy
Background and Aims: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by mutations in the CYP27A1 gene, leading to deficient sterol 27‐hydroxylase activity. This enzyme is critical for bile acid synthesis, and its dysfunction results in reduced chenodeoxycholic acid (CDCA) levels and subsequent accumulation of cholestanol in tissues. This study highlights the recent FDA approval of Ctexli (chenodiol), a synthetic CDCA formulation, as the first treatment option for CTX. Methods: A comprehensive literature search was performed using PubMed and Google Scholar, and relevant articles were identified that focused on the mechanism of action, clinical efficacy, and safety of chenodiol. Results: Data from the RESTORE Phase 3 trial demonstrated that chenodiol significantly reduced plasma cholestanol and urinary bile alcohol levels, with the most pronounced results observed in patients treated before the onset of irreversible neurological damage. The FDA approval of Ctexli validated these findings and established chenodiol as a reliable therapeutic option for CTX. Conclusion: The FDA approval of chenodiol marks a significant milestone in the management of CTX, providing a standardized and evidence‐based therapy for a previously neglected condition. Early diagnosis, broader screening, and global access to the drug will be key to improving outcomes and ensuring lasting clinical benefit.
- 26 November 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (12) , e71549
Open AccessFDA Approves First Targeted Treatment for Cerebrotendinous Xanthomatosis: A Perspective on a Landmark in Rare Lipid Storage Disease Therapy
Background and Aims: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by mutations in the CYP27A1 gene, leading to deficient sterol 27‐hydroxylase activity. This enzyme is critical for bile acid synthesis, and its dysfunction results in reduced chenodeoxycholic acid (CDCA) levels and subsequent accumulation of cholestanol in tissues. This study highlights the recent FDA approval of Ctexli (chenodiol), a synthetic CDCA formulation, as the first treatment option for CTX. Methods: A comprehensive literature search was performed using PubMed and Google Scholar, and relevant articles were identified that focused on the mechanism of action, clinical efficacy, and safety of chenodiol. Results: Data from the RESTORE Phase 3 trial demonstrated that chenodiol significantly reduced plasma cholestanol and urinary bile alcohol levels, with the most pronounced results observed in patients treated before the onset of irreversible neurological damage. The FDA approval of Ctexli validated these findings and established chenodiol as a reliable therapeutic option for CTX. Conclusion: The FDA approval of chenodiol marks a significant milestone in the management of CTX, providing a standardized and evidence‐based therapy for a previously neglected condition. Early diagnosis, broader screening, and global access to the drug will be key to improving outcomes and ensuring lasting clinical benefit.
- Open Access
- 27 September 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 7027-7037
Trends in lung cancer and pneumonia-associated mortality in the United States, 1999-2023: A CDC WONDER database study
Background: Lung cancer (LC) and pneumonia remain leading causes of mortality in the United States, with particularly severe impacts on vulnerable populations. While LC continues to be the deadliest cancer, pneumonia poses a critical threat to immunocompromised individuals, especially those with LC. This study examines 24-year trends in LC and pneumonia-related deaths, analyzing disparities across demographic groups and geographic regions to inform targeted public health strategies. Methods: We analyzed mortality data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database (1999-2023), calculating age-adjusted mortality rates (AAMRs) per 100 000 population. The study population included adults aged 25 + with LC and pneumonia listed as underlying or contributing causes of death. Joinpoint regression identified significant trends in mortality rates, stratified by sex, race/ethnicity, urbanization level, and US census region. Results: The analysis revealed a 51% decline in LC and pneumonia-related mortality over 24 years, with AAMRs dropping from 53.1 to 25.9 deaths per 100 000. The most dramatic improvement occurred between 2006 and 2009, when mortality rates fell by nearly 10% annually – likely reflecting advances in targeted cancer therapies, expanded screening programs, and stronger vaccination efforts. Despite overall progress, significant disparities persisted. Men died at twice the rate of women throughout the study period, with 2023 AAMRs of 32.6 for males versus 20.1 for females. Racial gaps remained troubling, as Black Americans consistently faced the highest mortality rates (65.7 in 1999 vs 30.7 in 2023), while Asian/Pacific Islanders saw an unexpected 10% mortality increase post-2021. Geographically, rural areas had 31% higher death rates than urban centers, and Southern states carried the heaviest burden across all regions. Conclusions: While national mortality trends show encouraging declines – particularly after 2006 – persistent disparities by sex, race, and geography highlight unmet public health needs. The findings call for tailored interventions addressing higher-risk groups, including enhanced screening in rural areas, culturally competent care for racial/ethnic minorities, and continued smoking cessation support. Sustained progress will require equitable access to emerging treatments and preventive services across all communities.
- 27 September 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 7027-7037
Open AccessTrends in lung cancer and pneumonia-associated mortality in the United States, 1999-2023: A CDC WONDER database study
Background: Lung cancer (LC) and pneumonia remain leading causes of mortality in the United States, with particularly severe impacts on vulnerable populations. While LC continues to be the deadliest cancer, pneumonia poses a critical threat to immunocompromised individuals, especially those with LC. This study examines 24-year trends in LC and pneumonia-related deaths, analyzing disparities across demographic groups and geographic regions to inform targeted public health strategies. Methods: We analyzed mortality data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database (1999-2023), calculating age-adjusted mortality rates (AAMRs) per 100 000 population. The study population included adults aged 25 + with LC and pneumonia listed as underlying or contributing causes of death. Joinpoint regression identified significant trends in mortality rates, stratified by sex, race/ethnicity, urbanization level, and US census region. Results: The analysis revealed a 51% decline in LC and pneumonia-related mortality over 24 years, with AAMRs dropping from 53.1 to 25.9 deaths per 100 000. The most dramatic improvement occurred between 2006 and 2009, when mortality rates fell by nearly 10% annually – likely reflecting advances in targeted cancer therapies, expanded screening programs, and stronger vaccination efforts. Despite overall progress, significant disparities persisted. Men died at twice the rate of women throughout the study period, with 2023 AAMRs of 32.6 for males versus 20.1 for females. Racial gaps remained troubling, as Black Americans consistently faced the highest mortality rates (65.7 in 1999 vs 30.7 in 2023), while Asian/Pacific Islanders saw an unexpected 10% mortality increase post-2021. Geographically, rural areas had 31% higher death rates than urban centers, and Southern states carried the heaviest burden across all regions. Conclusions: While national mortality trends show encouraging declines – particularly after 2006 – persistent disparities by sex, race, and geography highlight unmet public health needs. The findings call for tailored interventions addressing higher-risk groups, including enhanced screening in rural areas, culturally competent care for racial/ethnic minorities, and continued smoking cessation support. Sustained progress will require equitable access to emerging treatments and preventive services across all communities.
- Open Access
- 15 September 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 7763-7764
Monkeypox and measles: two scourges among children displaced by wars in the eastern region of the Democratic Republic of Congo
- 15 September 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 7763-7764
Open AccessMonkeypox and measles: two scourges among children displaced by wars in the eastern region of the Democratic Republic of Congo
- Open Access
- 12 September 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 7172-7176
Advancements in myelofibrosis management: a comprehensive analysis of Ojjaara (Momelotinib) therapy and clinical perspectives
Myelofibrosis (MF) is a rare and progressive blood disorder marked by fibrosis of the bone marrow, abnormal blood cell production, and often severe anemia. The disease is commonly associated with debilitating symptoms such as fatigue, weakness, and an enlarged spleen. Ojjaara (momelotinib), a selective inhibitor of Janus kinases (JAK1/2), offers a promising treatment option for patients with MF, particularly those suffering from anemia. By targeting the dysregulated JAK-STAT signaling pathway, Ojjaara helps restore normal blood cell production and reduces fibrosis in the bone marrow. Several clinical trials, including the MOMENTUM and SIMPLIFY-1 studies, have highlighted the drug’s ability to improve symptoms related to anemia, decrease spleen size, and enhance overall quality of life, with a manageable side effect profile. This review examines the role of momelotinib in treating MF, focusing on its mechanism, clinical benefits, patient selection criteria, monitoring strategies, potential side effects, and findings from key clinical trials. While promising, careful patient management is essential to minimize adverse effects and optimize the therapeutic benefits of momelotinib in MF treatment.
- 12 September 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 7172-7176
Open AccessAdvancements in myelofibrosis management: a comprehensive analysis of Ojjaara (Momelotinib) therapy and clinical perspectives
Myelofibrosis (MF) is a rare and progressive blood disorder marked by fibrosis of the bone marrow, abnormal blood cell production, and often severe anemia. The disease is commonly associated with debilitating symptoms such as fatigue, weakness, and an enlarged spleen. Ojjaara (momelotinib), a selective inhibitor of Janus kinases (JAK1/2), offers a promising treatment option for patients with MF, particularly those suffering from anemia. By targeting the dysregulated JAK-STAT signaling pathway, Ojjaara helps restore normal blood cell production and reduces fibrosis in the bone marrow. Several clinical trials, including the MOMENTUM and SIMPLIFY-1 studies, have highlighted the drug’s ability to improve symptoms related to anemia, decrease spleen size, and enhance overall quality of life, with a manageable side effect profile. This review examines the role of momelotinib in treating MF, focusing on its mechanism, clinical benefits, patient selection criteria, monitoring strategies, potential side effects, and findings from key clinical trials. While promising, careful patient management is essential to minimize adverse effects and optimize the therapeutic benefits of momelotinib in MF treatment.
- Open Access
- 18 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (10) , 6574-6579
Exploring the national burden and challenges in the fight against yellow fever in the Democratic Republic of Congo: a review
The Democratic Republic of Congo (DR Congo) is facing a public health emergency due to numerous infectious diseases, predominately yellow fever. Since 2015, numerous outbreaks of the illness have occurred in the country which resulted in detrimental impacts on the population. As of February 2024, the DR Congo has reported over 1,200 suspected yellow fever cases with an 11% case fatality rate. This represents a 22% increase compared to 2021 when 203 confirmed cases were reported with a 9% fatality rate. Although there is no specific medication to treat yellow fever, vaccination is proven to be the most effective method of prevention. Despite national and international efforts to combat the disease through vaccination campaigns, yellow fever continues to pose a significant threat. This is because vaccination efforts are limited by the inadequate infrastructure, poverty, poor sanitation and the presence of rebel groups in the DR Congo. Early diagnosis, the use of mosquito nets and insecticides, as well as raising awareness can furthermore aid in limiting transmission. This review explores the prevalence, diagnosis and prevention methods of yellow fever in the DR Congo, as well as the numerous obstacles faced by the country to eliminate it.
- 18 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (10) , 6574-6579
Open AccessExploring the national burden and challenges in the fight against yellow fever in the Democratic Republic of Congo: a review
The Democratic Republic of Congo (DR Congo) is facing a public health emergency due to numerous infectious diseases, predominately yellow fever. Since 2015, numerous outbreaks of the illness have occurred in the country which resulted in detrimental impacts on the population. As of February 2024, the DR Congo has reported over 1,200 suspected yellow fever cases with an 11% case fatality rate. This represents a 22% increase compared to 2021 when 203 confirmed cases were reported with a 9% fatality rate. Although there is no specific medication to treat yellow fever, vaccination is proven to be the most effective method of prevention. Despite national and international efforts to combat the disease through vaccination campaigns, yellow fever continues to pose a significant threat. This is because vaccination efforts are limited by the inadequate infrastructure, poverty, poor sanitation and the presence of rebel groups in the DR Congo. Early diagnosis, the use of mosquito nets and insecticides, as well as raising awareness can furthermore aid in limiting transmission. This review explores the prevalence, diagnosis and prevention methods of yellow fever in the DR Congo, as well as the numerous obstacles faced by the country to eliminate it.
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 5381-5384
Zoonoses in the Democratic Republic of Congo: anthrax outbreak in the province of Nord-Kivu has prompted a health alert
An abstract is unavailable. This article is available as a PDF only.
- 1 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 5381-5384
Open AccessZoonoses in the Democratic Republic of Congo: anthrax outbreak in the province of Nord-Kivu has prompted a health alert
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 31 July 2025
- Published by Springer Nature in Infection
- Vol. 53 (5) , 1645-1661
Efficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Introduction: Since late 2019, COVID-19 has had a catastrophic impact on public health. Ensitrelvir, a new antiviral targeting the SARS-CoV-2 main protease, has reduced viral replication and disease severity. This meta-analysis and systematic review assessed Ensitrelvir’s efficacy and safety in patients with mild-to-moderate COVID-19 symptoms. Methods: A comprehensive search was conducted in PubMed (Medline), Scopus, Embase, and CENTRAL up to July 2024 to retrieve randomized controlled trials (RCTs) comparing Ensitrelvir to placebo in adults with mild to moderate, RT-PCR–confirmed COVID-19. Outcomes were assessed at standardized time points, with viral RNA measured at day 4. Mean differences (MD) for continuous outcomes and risk ratios (RR) for binary outcomes, both with 95% confidence intervals (CIs), were calculated using the Mantel–Haenszel random-effects model. Efficacy outcomes included SARS-CoV-2 viral RNA, while safety outcomes included HDL, triglycerides, bilirubin, AST, headache, diarrhea, TEAEs, TRAEs, serious TEAEs, and treatment discontinuation. The quality of the included RCTs was assessed with the Cochrane Risk of Bias 2 (ROB2) tool. Results: The analysis included six RCTs with 2,793 participants: 1,860 received Ensitrelvir and 933 were given a placebo. Ensitrelvir gave significant results for reduced viral RNA levels of SARS-CoV-2 [MD: − 1.35; 95% CI − 1.58 to − 1.13; p < 0.01] and the incidence of lower cholesterol levels [RR: 8.83; 95% CI 4.05 to 19.27; p < 0.01] compared to the placebo group. However, it was associated with increased risks of decreased HDL levels, elevated triglycerides, increased bilirubin, more headaches, and a higher overall occurrence of treatment-emergent adverse events. Conclusion: Ensitrelvir effectively reduces viral load in COVID-19 patients, but its safety profile raises concerns due to significant adverse effects. The benefits must be carefully weighed against the risks, and further research is needed to confirm its role in treatment and to find ways to mitigate these adverse effects.
- 31 July 2025
- Published by Springer Nature in Infection
- Vol. 53 (5) , 1645-1661
Open AccessEfficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Introduction: Since late 2019, COVID-19 has had a catastrophic impact on public health. Ensitrelvir, a new antiviral targeting the SARS-CoV-2 main protease, has reduced viral replication and disease severity. This meta-analysis and systematic review assessed Ensitrelvir’s efficacy and safety in patients with mild-to-moderate COVID-19 symptoms. Methods: A comprehensive search was conducted in PubMed (Medline), Scopus, Embase, and CENTRAL up to July 2024 to retrieve randomized controlled trials (RCTs) comparing Ensitrelvir to placebo in adults with mild to moderate, RT-PCR–confirmed COVID-19. Outcomes were assessed at standardized time points, with viral RNA measured at day 4. Mean differences (MD) for continuous outcomes and risk ratios (RR) for binary outcomes, both with 95% confidence intervals (CIs), were calculated using the Mantel–Haenszel random-effects model. Efficacy outcomes included SARS-CoV-2 viral RNA, while safety outcomes included HDL, triglycerides, bilirubin, AST, headache, diarrhea, TEAEs, TRAEs, serious TEAEs, and treatment discontinuation. The quality of the included RCTs was assessed with the Cochrane Risk of Bias 2 (ROB2) tool. Results: The analysis included six RCTs with 2,793 participants: 1,860 received Ensitrelvir and 933 were given a placebo. Ensitrelvir gave significant results for reduced viral RNA levels of SARS-CoV-2 [MD: − 1.35; 95% CI − 1.58 to − 1.13; p < 0.01] and the incidence of lower cholesterol levels [RR: 8.83; 95% CI 4.05 to 19.27; p < 0.01] compared to the placebo group. However, it was associated with increased risks of decreased HDL levels, elevated triglycerides, increased bilirubin, more headaches, and a higher overall occurrence of treatment-emergent adverse events. Conclusion: Ensitrelvir effectively reduces viral load in COVID-19 patients, but its safety profile raises concerns due to significant adverse effects. The benefits must be carefully weighed against the risks, and further research is needed to confirm its role in treatment and to find ways to mitigate these adverse effects.
- Open Access
- 28 July 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 6228-6230
Atzumi for migraine: a new era of needle-free dihydroergotamine delivery
Migraine continues to affect a large portion of the population and remains difficult to treat effectively in many cases, especially when gastrointestinal symptoms interfere with medication absorption. Atzumi, a dihydroergotamine mesylate nasal powder, recently received U.S. Food and Drug Administration approval and represents a promising alternative. It uses a unique powder-based delivery system aimed at improving absorption and consistency of effect. Data from both early pharmacokinetic testing and a long-term safety study suggest that it works quickly and is generally well tolerated. Patients experienced meaningful relief, often without needing backup medications, and side effects were reported infrequently.
- 28 July 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 6228-6230
Open AccessAtzumi for migraine: a new era of needle-free dihydroergotamine delivery
Migraine continues to affect a large portion of the population and remains difficult to treat effectively in many cases, especially when gastrointestinal symptoms interfere with medication absorption. Atzumi, a dihydroergotamine mesylate nasal powder, recently received U.S. Food and Drug Administration approval and represents a promising alternative. It uses a unique powder-based delivery system aimed at improving absorption and consistency of effect. Data from both early pharmacokinetic testing and a long-term safety study suggest that it works quickly and is generally well tolerated. Patients experienced meaningful relief, often without needing backup medications, and side effects were reported infrequently.